Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib plus azacitidine in accelerated-phase or myeloid blast crisis chronic myeloid leukemia
2017-004674-34Phase 2Active
- Sponsor
- Centre Hospitalier de Versailles
- Start
- Jul 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ponatinib and azacitidine in chronic myeloid leukemia (CML) and chronic myelogenous leukemia (CML) (2 cohorts), sponsored by Centre Hospitalier de Versailles. Primary endpoint: Overall survival. Started Jul 2018; status: active.
02
Drugs
ponatinibazacitidine
03
Conditions
chronic myeloid leukemia (CML)chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2017-004674-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004674-34.